ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tofacitinib"

  • Abstract Number: 1338 • 2019 ACR/ARP Annual Meeting

    Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start

    Mojca Frank-Bertoncelj1, Oliver Distler 2, Tim Killeen 3, Kenneth Kwok 4, Lisy Wang 5, Caroline Ospelt 1 and Adrian Ciurea 1, 1University Hospital Zürich, Zürich, Switzerland, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Pfizer AG, Zürich, Switzerland, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT

    Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses…
  • Abstract Number: 1373 • 2019 ACR/ARP Annual Meeting

    Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice

    Tatiana Barbich1, Osvaldo Luis Cerda 2, Emilce Schneeberger 3 and Gustavo Citera 4, 1Instituto de Rehabilitación Psicofísica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Instituto de Rehabilitacion Psicofisica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 3Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: To evaluate the adherence to treatment with Tofacitinib in patients with Rheumatoid Arthritis (RA) using both versions of the self-questionnaire Compliance Questionnaire Rheumatology: CQR19…
  • Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting

    Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib

    James Harnett1, Timothy Smith 1, John Woolcott 2, David Gruben 3 and Christopher Murray 2, 1Pfizer Inc, New York, NY, 2Pfizer Inc, Collegeville, PA, 3Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…
  • Abstract Number: 1444 • 2019 ACR/ARP Annual Meeting

    Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials

    Gustavo Citera1, Rakesh Jain 2, Fedra Irazoque 3, Renato Guzman 4, Hugo Madariaga 5, David Gruben 6, Lisy Wang 6, Lori Stockert 7, Ming-Ann Hsu 8, Karina Santana 9, Abbas Ebrahim 10 and Dario Ponce de Leon 11, 1Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 2Texas Tech University School of Medicine, Lubbock, TX, 3Hospital Angeles Mocel, San Miguel, Mexico, 4Fundación Universitaria Juan N. Corpas e IDEARG, Bogota, Colombia, 5Clínica del Sur, Arequipa, Peru, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, Collegeville, PA, 8Pfizer Inc, Groton, 9Pfizer Inc, Mexico City, Mexico, 10Pfizer Inc, Collegeville, 11Pfizer Inc, Lima, Peru

    Background/Purpose: Depression and anxiety are common in patients (pts) with RA1 and can lead to reduced quality of life, functional capacity, and RA treatment response.2-4…
  • Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting

    Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis

    Gulsen Ozen1, Sofia Pedro2 and Kaleb Michaud1,2, 1Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS

    Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…
  • Abstract Number: 224 • 2018 ACR/ARHP Annual Meeting

    Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab

    Huifeng Yun, Fenglong Xie, Lang Chen and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Recent concern has been raised for a risk for venous thromboembolism (VTE) associated with janus kinase inhibitors among patients with RA who are already…
  • Abstract Number: 525 • 2018 ACR/ARHP Annual Meeting

    Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program

    Gustavo Citera1, Eduardo Mysler2, Hugo Madariaga3, Mario H Cardiel4, Oswaldo Castañeda5, Aryeh Fischer6, Pascal Richette7, Sandra Chartrand8, Jin Kyun Park9, Sander Strengholt10, Jose L Rivas11, Amit Thorat12, Tanya Girard13, Kenneth Kwok14, Lisy Wang15 and Dario Ponce de Leon16, 1Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Organización Médica de Investigación, Buenos Aires, Argentina, 3Clínica del Sur, Arequipa, Peru, 4Centro de Investigación Clínica de Morelia, Morelia, Mexico, 5Clínica Anglo Americana, Lima, Peru, 6Department of Medicine, University of Colorado, Denver, CO, 7Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, 8Department of Medicine, Hôpital Maisonneuve-Rosemont affiliated to Université de Montréal, Montréal, QC, Canada, 9Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), 10Pfizer Inc, Capelle aan den IJssel, Netherlands, 11Pfizer SLU, Madrid, Spain, 12Pfizer Ltd, Mumbai, India, 13Pfizer Inc, Montréal, QC, Canada, 14Pfizer Inc, New York, NY, 15Pfizer Inc, Groton, CT, 16Pfizer Inc, Lima, Peru

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Interstitial lung disease (ILD) is a common extra-articular manifestation of RA,1 and…
  • Abstract Number: 580 • 2018 ACR/ARHP Annual Meeting

    Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry

    Stanley Cohen1, Heather J Litman2, Connie Chen3, Tatjana Lukic3, Ann Madsen3, Liza Takiya4, Kimberly J Dandreo2, Taylor Blachley2 and Jeffrey Greenberg2, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Corrona LLC, Waltham, MA, 3Pfizer Inc, New York, NY, 4Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, originally approved at 5 mg twice daily (BID). In 2016, an extended-release…
  • Abstract Number: 581 • 2018 ACR/ARHP Annual Meeting

    Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX

    Stanley Cohen1, Boulos Haraoui2, Jeffrey R. Curtis3, Timothy Smith4, John Woolcott5, David Gruben6, Christopher W Murray5, Noriko Iikuni4, Andrew Koenig5 and James Harnett4, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Institut de Rhumatologie de Montreal, Montreal, QC, Canada, 3University of Alabama at Birmingham, Birmingham, AL, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, in combination with MTX or other non‑biologic (nb)DMARDs, or as monotherapy. Two…
  • Abstract Number: 606 • 2018 ACR/ARHP Annual Meeting

    Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry

    Berrin Zengin1, Nevsun Inanc2, Servet Akar3, Gerçek Can1, Ediz Dalkiliç4, Abdurrahman Tufan5, Soner Senel6, Suleyman Serdar Koca7, Handan Yarkan1, Yavuz Pehlivan8, Zeynep Erturk9, Berna Goker5, Haner Direskeneli2, Merih Birlik1, Nurullah Akkoc10 and Fatos Onen1, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 2Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 3Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, 4Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 5Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, 6Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, 7Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, 8Rheumatology, Uludag University, Faculty of Medicine, Bursa, Turkey, 9Rheumatology, Marmara University Faculty of Medicine, istanbul, Turkey, 10Rheumatology, İzmir, Turkey, İzmir, Turkey

    Background/Purpose: Tofacitinib, a JAK3 inhibitor has been used to treat patients with rheumatoid arthritis (RA) in Turkey since 2015. The aim of this study was…
  • Abstract Number: 607 • 2018 ACR/ARHP Annual Meeting

    Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial

    Tsutomu Takeuchi1, Josef S. Smolen2, Roy Fleischmann3, Noriko Iikuni4, Haiyun Fan5, Koshika Soma6, Ermeg Akylbekova7 and Tomohiro Hirose8, 1Keio University, Tokyo, Japan, 2Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 3Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, Groton, CT, 7IQVIA, Durham, NC, 8Pfizer Japan Inc, Tokyo, Japan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055), a 12-month, global, Phase 3b/4 study, demonstrated that in…
  • Abstract Number: 685 • 2018 ACR/ARHP Annual Meeting

    Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

    William FC Rigby1, Gerd R. Burmester2, Oliver FitzGerald3, Valderilio F Azevedo4, Peter Nash5, Thijs Hendrikx6, Daniela Graham7, Cunshan Wang7 and Thomas Jones6, 1Geisel School of Medicine at Dartmouth, Lebanon, NH, 2Charité – University Medicine Berlin, Berlin, Germany, 3Department of Rheumatology, St Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College, Dublin, Ireland, 4Universidade Federal do Paraná, Curitiba, Brazil, 5University of Queensland, Brisbane, Australia, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is…
  • Abstract Number: 1018 • 2018 ACR/ARHP Annual Meeting

    Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritis and Psoriatic Arthritis.

    Viviana Marzaioli1, Mary Canavan1, Achilleas Floudas1, Siobhan C. Wade1, Candice Low2, Douglas J. Veale2 and Ursula Fearon1, 1Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, 2Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland

    Background/Purpose: Tofacinitib (Pfizer) is an oral Janus kinase inhibitor, recently approved for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Although its mechanism…
  • Abstract Number: 1515 • 2018 ACR/ARHP Annual Meeting

    Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance

    Naoto Tamura1, Masataka Kuwana2, Tatsuya Atsumi3, Syuji Takei4, Masayoshi Harigai5, Takao Fujii6, Hiroaki Matsuno7, Tsuneyo Mimori8, Shigeki Momohara9, Kazuhiko Yamamoto10, Yoshinari Takasaki11, Kazuto Nomura12, Yutaka Endo12, Tomohiro Hirose12, Yosuke Morishima12, Naonobu Sugiyama12, Noritoshi Yoshii12 and Michiaki Takagi13, 1Juntendo University, Tokyo, Japan, 2Nippon Medical School, Tokyo, Japan, 3Hokkaido University, Sapporo, Japan, 4Medical Center for Children, Kagoshima, Japan, 5Tokyo Women’s Medical University, Tokyo, Japan, 6Wakayama Medical University, Wakayama, Japan, 7Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 8Kyoto University, Kyoto, Japan, 9Hakkeikai Inc Medical Institution, Shizuoka, Japan, 10The University of Tokyo, Tokyo, Japan, 11Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan, 12Pfizer Japan Inc, Tokyo, Japan, 13Yamagata University Faculty of Medicine, Yamagata, Japan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The efficacy and safety of tofacitinib have been demonstrated in patients (pts)…
  • Abstract Number: 1516 • 2018 ACR/ARHP Annual Meeting

    Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance

    Naoto Tamura1, Masataka Kuwana2, Tatsuya Atsumi3, Syuji Takei4, Masayoshi Harigai5, Takao Fujii6, Hiroaki Matsuno7, Tsuneyo Mimori8, Shigeki Momohara9, Kazuhiko Yamamoto10, Yoshinari Takasaki11, Kazuto Nomura12, Yutaka Endo12, Tomohiro Hirose12, Yosuke Morishima12, Naonobu Sugiyama12, Noritoshi Yoshii12 and Michiaki Takagi13, 1Juntendo University, Tokyo, Japan, 2Nippon Medical School, Tokyo, Japan, 3Hokkaido University, Sapporo, Japan, 4Medical Center for Children, Kagoshima, Japan, 5Tokyo Women’s Medical University, Tokyo, Japan, 6Wakayama Medical University, Wakayama, Japan, 7Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 8Kyoto University, Kyoto, Japan, 9Hakkeikai Inc Medical Institution, Shizuoka, Japan, 10The University of Tokyo, Tokyo, Japan, 11Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan, 12Pfizer Japan Inc, Tokyo, Japan, 13Yamagata University Faculty of Medicine, Yamagata, Japan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Previously, the efficacy and safety of tofacitinib were demonstrated in patients (pts)…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology